MedCity News March 18, 2020
Molecular diagnostics companies have laid the foundation for nothing short of a revolution in cancer care — it’s time for the medtech sector to develop tools to make genomic testing accessible to the masses.
The global molecular diagnostics market for cancer care was valued at $1.6 billion last year, up more than 10 percent from 2018. That’s just a fraction of the entire molecular diagnostics field, but still staggering for a medical arena that’s still in its infancy.
It’s even more impressive when you look at how few physicians are actually ordering molecular diagnostics tests for cancer patients. Some studies have shown that despite 75 percent of physicians believing that genomic testing improves patient outcomes, only four percent routinely order...
Today's Sponsors
Today's Sponsor